The global single cell genome sequencing market size was estimated to be USD 2.65 billion in 2023 and is expected to reach at USD 13.74 billion by 2034 with a CAGR of 16.14% during the forecast period 2024-2034. Surge in prevalence of chronic diseases such as diabetes, cancer, & arthritis, growing technological advancements in single-cell genome sequencing (SCGS), rising geriatric population, increasing emphasis on product development, surge in research & development activities, growing collaborations within market players, rising funding for the development of advanced genome sequencing instruments, and increasing trend of introducing groundbreaking single-cell genome sequencing platforms are some of the key factors boosting the market growth.
Increasing trend of introducing groundbreaking single-cell genome sequencing platforms is predicted to boost the market growth during the forecast period. Single-cell genome sequencing is a highly detailed process involving the isolation, amplification, and sequencing of genes within an individual cell. It leverages next-generation sequencing technology to provide insights into the inner workings of a cell. This advanced technology is particularly valuable for unraveling biological processes and elucidating organisms that are challenging to culture in vitro. Single-cell genome sequencing finds widespread applications in fields such as neurology, immunology, and cancer research. For instance, in May 2023, Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, has introduced significant enhancements to the Tapestri Platform and its core chemistry. These improvements enable the robust identification of rare cells for various applications. With the Tapestri® v3 chemistry, researchers can detect minute numbers of single cells that were previously challenging to identify, yet could have a substantial impact on disease in subtle ways.
By product, instruments was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the rapid progress and integration of technologically advanced instruments and solutions, specifically tailored to align with the evolving developments in healthcare technology and heightened emphasis among market players on the development & production of these instruments. Additionally, reagents is predicted to grow at fastest CAGR during the forecast period owing to the rising technological advancements and surge in launch of novel products. For instance, in March 2022, Sengenics has unveiled the commercial release of the i-Ome Protein Array Kit. This kit includes slide-based, high-density protein microarrays that feature over 1600 immobilized, full-length, properly folded human proteins.
By technology, PCR was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the growing adoption of PCR technology in genome sequencing, rising collaborations within market players, and increasing launch of advanced technologies. For instance, in July 2022, Bio-Rad has introduced the CFX Opus Deepwell real-time PCR detection system. This system is designed to facilitate research in the development of nucleic acid detection assays. Additionally, NGS is predicted to grow at fastest CAGR during the forecast period owing to its wide range of applications in cancer-related research, extensive research & development (R&D) efforts, and rising technological advancements.
By workflow, genomic analysis was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the increasing funding for research & development efforts and rising adoption of genomic analysis products. Additionally, single cell isolation is predicted to grow at fastest CAGR during the forecast period owing to the surge in funding for cell-based research, growing number of patients suffering from cancer, and increasing launch of advanced devices. For instance, in May 2023, Becton, Dickinson and Company has released the BD FACSDiscover S8 Cell Sorter, an innovative cell sorting instrument featuring two groundbreaking technologies. These technologies empower researchers to uncover previously hidden and more detailed information about cells, which was not achievable in traditional flow cytometry experiments.
By disease area, cancer was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the increasing prevalence of colorectal, prostate, & breast cancer, surge in research & development activities. For instance, in October 2022, Researchers from the University of British Columbia (UBC) and the BC Cancer Research Institute conducted cancer-related research that demonstrated the power of single-cell genome sequencing in providing fresh insights into lethal cancers. These researchers sequenced the genomes of individual cells obtained from the biopsies of 158 BC Cancer patients, enabling them to observe the evolutionary processes occurring within each individual cell. Additionally, prenatal diagnosis is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of medical tests & procedures conducted during pregnancy to identify potential health concerns or abnormalities in the developing fetus, and SCGS (Single-Cell Genome Sequencing) offers superior resolution and accuracy when compared to traditional sequencing methods.
By application, circulating cells was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the growing utilization of circulating tumor cells (CTCs) in clinical applications as biomarkers for cancer detection, and increasing collaborations within market players. Additionally, genomic variation is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of research & clinical trials and rising launch of novel solutions. For instance, in January 2023, Bioinformatics specialists at Singleron Biotechnologies, a prominent player in single-cell sequencing, have created a novel single-cell eQTL (expression quantitative trait loci) analysis workflow. This workflow harnesses single-cell RNA sequencing (scRNAseq) and whole genome sequencing (WGS) data to forecast cell-type specific eQTLs.
By end-user, academic & research laboratories was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the surge in number of genomic centers, growing funding for life science research, and increasing number of medical colleges & institutions. Additionally, biotechnology & biopharmaceutical companies is predicted to grow at fastest CAGR during the forecast period owing to the medical institutions & hospitals are increasingly relying on these companies for research access, results, equipment, and related support services, numerous biotechnology companies are implementing various competitive strategies to extend their lead, and rising research & development activities. For instance, in October 2023, BioSkryb Genomics, a company dedicated to advancing single-cell analysis and providing a comprehensive multiomic perspective of the cellular ecosystem from research to diagnostics, has announced its intention to present a substantial body of new research at the ASHG 2023 Annual Meeting in Washington, D.C. This research encompasses single-cell multiomic data, single-cell whole genome sequencing, and comprehensive multiomic profiling.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing incidence of cancer & various chronic diseases, increasing advancements in technology, surge in research & development efforts, rising introduction of new products. For instance, in October 2022, PacBio has introduced its Multiplexed Arrays Sequencing (MAS-Seq) kit in collaboration with the Broad Institute of MIT and Harvard and 10x Genomics. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in geriatric population, rising prevalence of chronic diseases, growing healthcare infrastructure, and increasing launch of innovative platform. For instance, in August 2023, MGI, a company dedicated to developing fundamental tools and technology for the life sciences, has revealed the launch of the MGISP-NEX and MGIFLP-L50 automation platforms at Medlab Asia & Asia Health 2023, occurring from August 16-18 at the IMPACT Exhibition Center in Bangkok, Thailand. These two highly automated systems will be open for orders in specific countries starting at the end of September 2023, thereby enhancing MGI's comprehensive product range, which encompasses genetic sequencing, automation, single-cell analysis, bioinformatics (BIT), and more.
Increasing trend of introducing groundbreaking single-cell genome sequencing platforms is predicted to boost the market growth during the forecast period. Single-cell genome sequencing is a highly detailed process involving the isolation, amplification, and sequencing of genes within an individual cell. It leverages next-generation sequencing technology to provide insights into the inner workings of a cell. This advanced technology is particularly valuable for unraveling biological processes and elucidating organisms that are challenging to culture in vitro. Single-cell genome sequencing finds widespread applications in fields such as neurology, immunology, and cancer research. For instance, in May 2023, Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, has introduced significant enhancements to the Tapestri Platform and its core chemistry. These improvements enable the robust identification of rare cells for various applications. With the Tapestri® v3 chemistry, researchers can detect minute numbers of single cells that were previously challenging to identify, yet could have a substantial impact on disease in subtle ways.
By product, instruments was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the rapid progress and integration of technologically advanced instruments and solutions, specifically tailored to align with the evolving developments in healthcare technology and heightened emphasis among market players on the development & production of these instruments. Additionally, reagents is predicted to grow at fastest CAGR during the forecast period owing to the rising technological advancements and surge in launch of novel products. For instance, in March 2022, Sengenics has unveiled the commercial release of the i-Ome Protein Array Kit. This kit includes slide-based, high-density protein microarrays that feature over 1600 immobilized, full-length, properly folded human proteins.
By technology, PCR was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the growing adoption of PCR technology in genome sequencing, rising collaborations within market players, and increasing launch of advanced technologies. For instance, in July 2022, Bio-Rad has introduced the CFX Opus Deepwell real-time PCR detection system. This system is designed to facilitate research in the development of nucleic acid detection assays. Additionally, NGS is predicted to grow at fastest CAGR during the forecast period owing to its wide range of applications in cancer-related research, extensive research & development (R&D) efforts, and rising technological advancements.
By workflow, genomic analysis was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the increasing funding for research & development efforts and rising adoption of genomic analysis products. Additionally, single cell isolation is predicted to grow at fastest CAGR during the forecast period owing to the surge in funding for cell-based research, growing number of patients suffering from cancer, and increasing launch of advanced devices. For instance, in May 2023, Becton, Dickinson and Company has released the BD FACSDiscover S8 Cell Sorter, an innovative cell sorting instrument featuring two groundbreaking technologies. These technologies empower researchers to uncover previously hidden and more detailed information about cells, which was not achievable in traditional flow cytometry experiments.
By disease area, cancer was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the increasing prevalence of colorectal, prostate, & breast cancer, surge in research & development activities. For instance, in October 2022, Researchers from the University of British Columbia (UBC) and the BC Cancer Research Institute conducted cancer-related research that demonstrated the power of single-cell genome sequencing in providing fresh insights into lethal cancers. These researchers sequenced the genomes of individual cells obtained from the biopsies of 158 BC Cancer patients, enabling them to observe the evolutionary processes occurring within each individual cell. Additionally, prenatal diagnosis is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of medical tests & procedures conducted during pregnancy to identify potential health concerns or abnormalities in the developing fetus, and SCGS (Single-Cell Genome Sequencing) offers superior resolution and accuracy when compared to traditional sequencing methods.
By application, circulating cells was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the growing utilization of circulating tumor cells (CTCs) in clinical applications as biomarkers for cancer detection, and increasing collaborations within market players. Additionally, genomic variation is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of research & clinical trials and rising launch of novel solutions. For instance, in January 2023, Bioinformatics specialists at Singleron Biotechnologies, a prominent player in single-cell sequencing, have created a novel single-cell eQTL (expression quantitative trait loci) analysis workflow. This workflow harnesses single-cell RNA sequencing (scRNAseq) and whole genome sequencing (WGS) data to forecast cell-type specific eQTLs.
By end-user, academic & research laboratories was the highest revenue-grossing segment in the global single cell genome sequencing market in 2023 owing to the surge in number of genomic centers, growing funding for life science research, and increasing number of medical colleges & institutions. Additionally, biotechnology & biopharmaceutical companies is predicted to grow at fastest CAGR during the forecast period owing to the medical institutions & hospitals are increasingly relying on these companies for research access, results, equipment, and related support services, numerous biotechnology companies are implementing various competitive strategies to extend their lead, and rising research & development activities. For instance, in October 2023, BioSkryb Genomics, a company dedicated to advancing single-cell analysis and providing a comprehensive multiomic perspective of the cellular ecosystem from research to diagnostics, has announced its intention to present a substantial body of new research at the ASHG 2023 Annual Meeting in Washington, D.C. This research encompasses single-cell multiomic data, single-cell whole genome sequencing, and comprehensive multiomic profiling.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing incidence of cancer & various chronic diseases, increasing advancements in technology, surge in research & development efforts, rising introduction of new products. For instance, in October 2022, PacBio has introduced its Multiplexed Arrays Sequencing (MAS-Seq) kit in collaboration with the Broad Institute of MIT and Harvard and 10x Genomics. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in geriatric population, rising prevalence of chronic diseases, growing healthcare infrastructure, and increasing launch of innovative platform. For instance, in August 2023, MGI, a company dedicated to developing fundamental tools and technology for the life sciences, has revealed the launch of the MGISP-NEX and MGIFLP-L50 automation platforms at Medlab Asia & Asia Health 2023, occurring from August 16-18 at the IMPACT Exhibition Center in Bangkok, Thailand. These two highly automated systems will be open for orders in specific countries starting at the end of September 2023, thereby enhancing MGI's comprehensive product range, which encompasses genetic sequencing, automation, single-cell analysis, bioinformatics (BIT), and more.
Segmentation: Single Cell Genome Sequencing Market Report 2023 - 2034
Single Cell Genome Sequencing Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Reagents
- Instruments
Single Cell Genome Sequencing Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Microarray
- PCR
- MDA
- NGS
- qPCR
Single Cell Genome Sequencing Market Analysis & Forecast by Workflow 2023 - 2034 (Revenue USD Bn)
- Sample Preparation
- Genomic Analysis
- Single Cell Isolation
Single Cell Genome Sequencing Market Analysis & Forecast by Disease Area 2023 - 2034 (Revenue USD Bn)
- Immunology
- Microbiology
- Neurobiology
- Cancer
- Prenatal Diagnosis
- Others
Single Cell Genome Sequencing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Genomic Variation
- Circulating Cells
- Subpopulation Characterization
- Cell Differentiation/Reprogramming
- Others
Single Cell Genome Sequencing Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Clinics
- Biotechnology & Biopharmaceutical Companies
- Academic & Research Laboratories
- Others
Single Cell Genome Sequencing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Single Cell Genome Sequencing Market: Product Estimates & Trend Analysis
8. Single Cell Genome Sequencing Market: Technology Estimates & Trend Analysis
9. Single Cell Genome Sequencing Market: Workflow Estimates & Trend Analysis
10. Single Cell Genome Sequencing Market: Disease Area Estimates & Trend Analysis
11. Single Cell Genome Sequencing Market: Application Estimates & Trend Analysis
12. Single Cell Genome Sequencing Market: End-user Estimates & Trend Analysis
13. Regional Market Analysis
14. North America Single Cell Genome Sequencing Market
15. Europe Global Single Cell Genome Sequencing Market
16. Asia Pacific Global Single Cell Genome Sequencing Market
17. Latin America Global Single Cell Genome Sequencing Market
18. MEA Global Single Cell Genome Sequencing Market
19. Competitor Analysis
20. Company Profiles
Companies Mentioned
- F. Hoffmann-La-Roche Ltd.
- Novogene
- 10x Genomics
- Illumina Inc.
- QIAGEN
- Bio-Rad Laboratories
- BGI
- Pacific Biosciences
- Fluidigm
- Thermo Fisher Scientific Inc.
- Oxford Nanopore Technologies
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.65 Billion |
| Forecasted Market Value ( USD | $ 13.74 Billion |
| Compound Annual Growth Rate | 16.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
